

Research Activities Newsletter

The latest news and announcements



In This Issue

In the News: Congratulations to the following awardees!!!	2
Notice of Intent to Publish	3
Notice of Special Interest	4
NIH Funding Opportunities: Request for Applications (RFA).....	5
• HIV/AIDS	5
• Miscellaneous	5
NIH Funding Opportunities (PAR).....	6
• Addictions.....	6
• HIV/AIDS	6
• Cancer.....	6
• Miscellaneous	7
NIH Funding Opportunities: Program Announcements (PA)	8
Foundation Opportunities.....	8
Limited Submissions	9
Research Opportunities from Past Newsletters	9
Words to Live By	9


In the News: Congratulations to the following awardees!!!



Hailey Banack, Research Assistant Professor of Epidemiology and Environmental Health is PI on a continuation award from the National Cancer Institute/NIH for the research study project entitled, *Ms. LILAC: Muscle Mass in the Life and Longevity After Cancer (LILAC) Study*. The study results will contribute to the development of public health recommendations and intervention strategies to prevent low muscle mass and associated adverse health outcomes in older and long-term cancer survivors. Co-Investigators from EEH include **Jean Wactawski-Wende**, Dean of SPHP and SUNY Distinguished Professor, and **Heather Ochs-Balcom**, Associate Professor.



Erin Brunelle, Director, CAT Client Services, is PI on three renewal awards from the NYS Justice Center for the Protection of People with Special Needs. The projects are entitled, *Technology-Related Assistance for Individuals with Disabilities (TRIAD) Program*; *TRIAD Program – Money Follows People*; and *TRIAD Program – ACCESS/VR*. The TRIAD Programs seek to increase awareness of, use, and implementation of assistive technology (AT) and provide information and referrals to improve the function, participation, and independence of individuals of all ages with disabilities.




Changxing Ma, Associate Professor of Biostatistics, is PI on a new IPA Agreement with the United States Department of Veterans Affairs Medical Center Kansas City for the project entitled, *Statistical Support for NR-VETS Clinical Trial at Kansas City VA*. The study is a double-blind randomized controlled trial to investigate the benefits of nicotinamide riboside (NR) for functional and cognitive benefits.



Pauline Mendola, Professor and Chair of Epidemiology and Environmental Health, is PI on a new award from the University of Maryland/US Department of Energy for the research project entitled, *Determination of the Health and Economic Benefits of Carbon Capture and Sequestration*. The goal of this proposal is to estimate the impact of carbon capture and sequestration technology on human health outcomes as a function of improvements in air quality, as the intermediate cause.



Kirkwood Personius, Clinical Associate Professor of Rehabilitation Science, is Co-I on a continuation award from the National Institute of Allergy and Infectious Diseases/NIH (PI: Elizabeth Wohlfert, Microbiology & Immunology) for the research project entitled, *T Regulatory Cell Responses in Toxoplasma-infected Muscle*. The research continues to identify how T-bet drives the pathogenic function of Tregs in infected muscle and identify the relevant cellular targets of amphiregulin in infected muscle during *Toxoplasma* infection.



Ghazala Saleem, Assistant Professor of Rehabilitation Science, is PI on a new IPA Agreement with the Veterans Administration for the project entitled, *Development of a Problem-Solving Intervention to Address Intimate Partner Violence and Behavioral Health Sequelae*. Intimate partner violence (IPV) is a major health concern among women Veterans, with lifetime prevalence estimates far exceeding those documented among civilian women (33 vs. 24%). Scalable interventions that can address the complex psychosocial, neurobehavioral, and environmental safety needs of women Veterans who have experienced IPV at point-of-service, are critically needed. One such intervention is the problem-solving approach that targets direct skill building on several biopsychosocial levels, including relational and environmental safety planning. In this study, the researchers propose to use the problem-solving approach to address psychosocial and neurobehavioral deficits in survivors of IPV.



Gregory Wilding, Professor of Biostatistics, is Co-I on a new award from the National Institute on Drug Abuse/NIH (PI: Eunhee Park, Nursing) for the research project entitled, *Measuring E-cigarette Use in Real Time via Wearable Sensor*. The goal of the research project is to validate the use of sensors integrated into a wrist-worn device (*Fitbit*), to accurately assess e-cigarette use in real time. In this way, it may be possible to measure youth e-cigarette use objectively and comprehensively, in the participants' natural environment. The validity of the e-cigarette use *Fitbit* data will be compared to video-recorded data in the laboratory setting. Researchers will examine the usability as well as the validity of the *Fitbit* e-cigarette use data by comparing it to verified data reported daily via participants' smartphones.

Congratulations to the following SPHHP faculty who were awarded new grants (as PI) in the SPHHP's 2024 Pilot Funding Program:



Heather Orom, Associate Professor of Community Health and Health Behavior and Associate Dean for Equity, Diversity and Inclusion, is PI for the project entitled, *Pilot Study to Demonstrate the Feasibility of Using Social Media Nano-Influencers to Disseminate Colorectal Cancer Screen Messages*.



Kirkwood Personius, Clinical Associate Professor of Rehabilitation Science, is PI for the project entitled, *Partial Reprogramming of Muscle to a 'Pro-Regenerative' State Via NANOG to Improve Recovery from Peripheral Nerve Injury (PNI) or Muscle Injury*.



John Violanti, Research Professor of Epidemiology and Environmental Health, is PI for the project entitled, *Neurological Injury among Police Officers*.

Congratulations to the following SPHHP faculty who were awarded new grants (as PI or Co-I) in University at Buffalo's 2024 Clinical and Translational Science Institute Pilot Studies Program:



Nicholas Felicione, Assistant Professor of Community Health and Health Behavior and **Zhongzheng Niu**, Assistant Professor Epidemiology and Environmental Health are Co-Investigators (PI: Xiaozhong Wen, Pediatrics) for the project entitled, *Simultaneous Versus Stepwise Cessation of Dual Use of Cigarettes and E-Cigarettes During Pregnancy Among Mothers with Low Incomes*.



David Hostler, Professor and Chair of Exercise and Nutrition Sciences and **Jennifer Temple**, Professor of Exercise and Nutrition Sciences and Community Health and Health Behavior, are Co-Investigators (PI: Leonard Epstein, Pediatrics) for the project entitled, *Effect of Meal Timing and Dietary Changes on Metabolic and Behavioral Factors Involved in the Food Insecurity-Obesity Paradox*.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health and Associate Dean for Translational and Team Sciences and **Renee Cadzow**, Assistant Professor of Epidemiology and Environmental Health are Co-Investigators (PI: Liise Kayler, Surgery) for the project entitled, *Supporting Live Kidney Donor Outreach in Low-income Communities*.



Gregory Wilding, Professor of Biostatistics is Co-Investigator (PI: Leslie Bisson, Orthopaedics) for the project entitled, *Piloting a Hands-only CPR/AED Education and Outreach Program to Improve Implementation of Health Care Interventions in Underserved Communities in Western New York*.

Notice of Intent to Publish

[NOT-OD-25-055](#)

Notice of Intent to Publish a Funding Opportunity Announcement for Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)

This Notice is to inform the extramural research community that the NIH Tobacco Regulatory Science Program (TRSP), participating NIH Institutes and Centers (ICs), and the United States Food and Drug Administration Center for Tobacco

Products (CTP) intend to issue a NOFO seeking R03 Small Grant Program applications for new High-Priority Research Topics in Tobacco Regulatory Science. This NOFO will seek to support New Investigators (including Early-Stage Investigators and investigators who have not successfully competed for independent NIH funding), in the biomedical, behavioral, and social sciences who are in the early stages of establishing independent careers in tobacco regulatory research but have not yet received any grant to support research in tobacco regulatory science. The NOFO will solicit applications to support new high-priority biomedical and behavioral research that will provide scientific data to inform the regulation of tobacco products to protect public health. This NOFO will include the new simplified peer review framework (SRF) and the Plan for Enhancing Diverse Perspectives. The NOFO is expected to be published in Spring 2025, with an expected application due date in Summer 2025.

[NOT-AA-25-002](#)

Notice of Intent to Publish a Funding Opportunity Announcement – Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional)

The new NOFO will use the NIH Program Project mechanism to support cross-cutting research on alcohol and HIV/AIDS. NIAAA seeks to encourage research that can be translated into interventions in order to reduce infection and transmission of HIV. The goals of the proposed center must be consistent with the priorities as described in the NIH Office of AIDS Research (OAR), [NIH Strategic Plan for HIV and HIV-Related Research](#). The NOFO will solicit applications for human studies that will advance operations or implementation research in the context of alcohol and HIV/AIDS by facilitating the development of: (1) broader systems approaches for monitoring complex HIV and alcohol-related patient outcomes including frailty, morbidity and mortality, and (2) interventions to reduce the impact of alcohol and alcohol-related comorbidities on HIV disease progression and transmission in the context of aging. The NOFO is expected to be published in Summer 2025 with an expected application due date in Fall 2025.

Notice of Special Interest

[NOT-HL-24-032](#)

Understanding and Addressing Weight Stigma, Bias, and Discrimination to Promote Health Equity

The purpose of this NOSI is to encourage and support research and career development training to elucidate the mechanisms and consequences of weight stigma, bias, and discrimination in children and adults with overweight or obesity. A secondary objective is to evaluate the effects of obesity-related interventions or policies that address weight bias and/or its consequences (e.g., weight stigma and discrimination) in affected groups. This notice applies to due dates on or after February 12, 2025, and subsequent receipt dates through May 8, 2028.

[NOT-CA-25-002](#)

Mechanisms Driving Obesity and Prostate Cancer Risk

The purpose of this NOSI is to promote studies examining the mechanisms by which obesity drives aggressive prostate cancer (PCa) risk. About 80% of overall PCa is non-aggressive. The biologic mechanisms driving both overall and aggressive PCa are uncertain. The identification of differences in the mechanisms driving aggressive vs. overall (mostly non-aggressive) disease are critical to optimizing clinical care among men who develop the disease. PCa has an outsized impact on African Americans who are more likely to develop aggressive disease and twice as likely to die from the disease compared to other racial and ethnic groups. This NOSI applies to application due dates on or after February 5, 2025, and subsequent receipt dates through January 7, 2028.

[NOT-CA-25-024](#)

Survivorship Research for People Living with Advanced and Metastatic Cancers

The National Cancer Institute is interested in applications proposing observational or intervention studies focused on survivorship for people living with advanced and metastatic cancers. Research interests include, but are not limited to, studies of 1) Clinical, genomic, and lifestyle factors associated with living longer with advanced or metastatic cancer, 2) Trajectories of physiological and psychological symptoms among people living with advanced or metastatic cancer, 3) Innovative models of health care delivery focused on the needs of people with advanced or metastatic cancer, 4) Prognostic awareness, uncertainty, and communication between providers, survivors, and caregivers, and 5) Strategies to address care needs for people living with advanced and metastatic cancers from populations that experience health or care disparities. Applications may focus on cancer survivors diagnosed at any age (childhood through adulthood) and may focus on a single cancer type or multiple cancer types. Applicants must adequately describe the population proposed in the study, including a justification for how this is a population living with likely incurable cancer. NCI strongly encourages applicants to include a plan for survivor engagement during the development, planning, and conduct of the proposed research project. This notice applies to application due dates on or after February 5, 2025, and subsequent application due dates through the expiration date of this NOSI (January 8, 2028).

[NOT-CA-25-006](#)**Communication and Decision-Making in a Complex and Dynamic Cancer Treatment Environment**

The purpose of this NOSI is to encourage research applications at the intersection of the complex and dynamic cancer treatment and cancer information contexts to understand and improve cancer treatment communication and decision-making. Proximal outcomes of interest may include communication quality, trust, and patient/clinician satisfaction, and distal outcomes may include adherence, symptom management, receipt of guideline-concordant care, and enhanced quality of life. Responsive applications may include observational or intervention research approaches. Approaches designed to reduce cancer disparities and improve equitable health outcomes are strongly encouraged. This notice applies to due dates on or after February 5, 2025, and subsequent receipt dates through September 7, 2028. This NOSI expires September 8, 2028.

NIH Funding Opportunities: Request for Applications (RFA)**HIV/AIDS**[RFA-MH-26-105](#) – (R01 Clinical Trial Optional)**Multimodal Artificial Intelligence to Accelerate HIV Clinical Care**

The overarching objective is to support data-driven, technological approaches to accelerate HIV diagnosis, prevention, and treatment efforts, which is closely aligned with the priorities of the NIMH Division of AIDS Research, the NIH Office of AIDS Research, and the U.S. Department of Health and Human Services. As such, this initiative supports the development of multimodal AI models to expand our capacity to address the dynamic, complex, and evolving HIV epidemic with three primary objectives: (1) development, adaptation, and evaluation of accurate, safe, efficient, and unbiased multimodal AI models to support a diverse range of HIV applications; (2) creation of knowledge graphs to enhance the interpretability and explainability for applications in HIV research, clinical care, and public health; and (3) exploration of synergistic integration of model-based explainability methods, knowledge graphs, and multimodal AI models for more precise model outputs and increased usability in HIV clinical care with a human-centered approach. Cross-disciplinary teams such as end-users, domain experts, patients/clients, community members, bioethicists, data scientists, software developers, engineers, and policymakers are encouraged. **Application Due Date:** March 27, 2025. **Expiration Date:** March 28, 2025.

[RFA-DA-25-074](#)- (R01 Clinical Trial Not Allowed)**Ex Vivo Models for Studies at the Intersection of HIV and Addictive Substance Use**

This notice of funding opportunity invites grant applications aimed at elucidating neuroimmune and neuronal-glia pathophysiological mechanisms underlying the interaction between addictive substances and HIV-associated neurological disorders (HAND) using ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC). **Application Due Date:** August 13, 2025. **Expiration Date:** August 14, 2025.

Miscellaneous[RFA-AT-25-002](#) – (R01 Clinical Trial Required)**Limited Competition: Advancing the Science of Complementary and Integrative Health Approaches to Improve Maternal Health Outcomes**

* *Please note: Eligibility is limited to currently funded IMPROVE investigators and their partners. See Notice for eligible funded recipients. Buffalo Prenatal Perinatal Network, Inc. is among one of the local organizations listed.*

This limited competition Notice invites investigators currently funded through the NIH Implementing a Maternal Health and Pregnancy Outcomes Vision for Everyone (IMPROVE) Initiative to develop applications to test the feasibility of complementary and integrative approaches with psychological and/or physical inputs (often called mind and body interventions) to promote healthy pregnancies and enhance maternal health outcomes. Currently funded IMPROVE investigators, particularly those of the Maternal Health Centers of Excellence, are encouraged to partner with investigators with complementary and integrative health expertise. Eligibility is limited to currently funded investigators of the IMPROVE Initiative. Applications submitted under this NOFO are expected to propose a multi-site feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial on a mind and body intervention to enhance maternal health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate Scientific/Research Contact person for the science area of the planned application. **Application Due Date:** May 5, 2025. **Expiration Date:** May 6, 2025.

NIH Funding Opportunities (PAR)

Addictions

[PAR-25-347](#) – (R36 Clinical Trials Not Allowed)

Substance Use/Substance Use Disorder Dissertation Research

The goal of this NOFO is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with the NIDA Strategic Plan ([2022-2026 NIDA Strategic Plan Director's Message / National Institute on Drug Abuse \(NIDA\) \(nih.gov\)](#)). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D)) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from individuals from diverse backgrounds, including those from underrepresented groups as described in the Notice of NIH's Interest in Diversity ([NOT-OD-20-031](#)). This NOFO is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** September 8, 2026.

[PAR-25-101](#) – (R21 Clinical Trial Optional)

Cutting-Edge Basic Research Awards (CEBRA)

The NIDA Cutting-Edge Basic Research Award is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders. It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** August 12, 2027.

HIV/AIDS

[PAR-25-354](#) – (R01 Clinical Trial Optional)

[PAR-25-355](#) – (R21 Clinical Trial Optional)

Multidisciplinary Studies of HIV/AIDS and Aging

This NOFO invites applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. Proposed research must be consistent with the HIV/AIDS Research Priorities outlined by NIH's Office of AIDS Research (OAR), as described in [NOT-OD-20-018](#). Please see Notice for interests by specific Institute, Centers, and Offices. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** January 8, 2027.

[PAS-25-073](#) – (R01 Clinical Trial Optional)

Priority HIV/AIDS Research with the Mission of NIDDK

This Notice of Funding Opportunity (NOFO) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that aligns with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in [NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding](#). **Application Due Dates:** multiple dates; see announcement. **Expiration Date:** January 8, 2028.

Cancer

[PAR-25-313](#) – (K99/R00 Clinical Trial Required)

NCI Pathway to Independence Award

This NOFO is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. The goal of the NCI Pathway to Independence Award program is to facilitate a timely transition of talented postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. **Application Due Dates:** multiple dates; see announcement. **Expiration Date:** October 15, 2027.

Miscellaneous

[PAS-25-102](#) – (R01 Clinical Trial Required)

Small R01's for Clinical Trials Targeting Diseases within the Mission of NIDDK

This Notice encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term proof-of-concept clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this NOFO should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required. This funding opportunity requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. **Application Due Dates:** multiple dates; see announcement. **Expiration Date:** May 8, 2026.

[PAR-25-369](#) – (R21 Clinical Trial Optional)

[PAR-25-370](#) – (R03 Clinical Trial Optional)

[PAR-25-371](#) – (R01 Clinical Trial Optional)

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant

The purpose of these NOFO's is to solicit applications for research projects that identify, examine, and address the ELSI of advances in genomics for individuals, families, communities, groups, institutions, and society. For Exploratory/Developmental Research Grant applications please see notice [PAR-25-369](#). Applications may propose studies using either single or mixed methods, which break new ground, extend previous discoveries in new directions, or develop preliminary data in preparation for larger studies. If your application should be for small, self-contained research projects, such as those that involve single investigators, please see notice [PAR-25-370](#). Projects of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data or the secondary analysis of existing data. Applications may propose studies using either single or mixed methods. Please see notice [PAR-25-371](#) if your application may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, and conceptual, legal, and normative analyses.

Application Due Date: multiple dates; see announcement. **Expiration Date:** November 19, 2026.

[PAR-25-091](#) – (R03 Clinical Trial Optional)

Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients

The National Institute of Diabetes and Digestive and Kidney Diseases announces a limited-competition program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant support during the latter years of the award period of their K award. The NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

Application Due Date: multiple dates; see announcement. **Expiration Date:** January 8, 2028.

[PAR-25-097](#) – (R21 Clinical Trial Optional)

Small Grants for New Investigators to Broaden Participation in Health-Related Research

The purpose of this NOFO is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects within the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases, or the National Human Genome Research Institute, or the National Institute of Biomedical Imaging and Bioengineering. This funding opportunity will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition of new and early stage investigators to research independence. In addition, this funding opportunity supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** January 8, 2028.

[PAR-25-312](#) – (R01 Clinical Trial Not Allowed)

Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk

This Notice establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence diet, physical activity, sleep, and/or weight and thus has the potential to lower rates of

chronic diseases, particularly in populations at risk for health disparities. This NOFO is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this NOFO must demonstrate that the evaluation of the policy or program of interest offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. Re-submissions are not eligible due to the time sensitive nature of this Notice. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** January 12, 2028.

NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-25-301](#)

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

Expiration Date: January 8, 2028

[PA-25-302](#)

NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

Expiration Date: January 8, 2028

[PA-25-303](#)

NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

Expiration Date: January 8, 2028

[PA-25-304](#)

NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)

Expiration Date: January 8, 2028

[PA-25-305](#)

NIH Research Project Grant (Parent R01 Clinical Trial Required)

Expiration Date: January 8, 2028

[PA-25-306](#)

NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)

Expiration Date: January 8, 2028

[PA-25-307](#)

NIH Exploratory/Developmental Research Project Grant (Parent R21 Basic Experimental Studies with Human Required)

Expiration Date: January 8, 2028

Foundation Opportunities

American Heart Association

[Health Care by Food Initiative](#)

This AHA HCXF Request for Proposals is designed to provide support for the development of a detailed trial protocol and grant to be submitted to a federal agency or other major funder focused on developing and testing ways in which FIM interventions can be an efficacious way to improve health outcomes. All proposed trials should meet the definition of Food Is Medicine, involving both the provision of food (via medically tailored meals, healthy food prescriptions, and/or medically tailored groceries) and identification of appropriate individuals through the healthcare system. Specific areas of clinical focus may include but are not limited to: 1) Individuals with Heart Failure, 2) Individuals with High-Risk Pregnancy, 3) Individuals with Cardiovascular-Kidney-Metabolic Disease, 4) Brain Health, including stroke, dementia, depression, and other neurological or mental health disorders. Other focus areas of interest include 1) Critical components of benefit design, including: dose, duration, tapering strategies, and ancillary services that facilitate efficacy in areas of clinical focus, 2) Implementation in rural settings, 3) Incorporation of Artificial Intelligence (AI) or other technologies to cost-effectively provide personalization at scale, and 4) Testing of ways to achieve sustained behavioral change. **Application Due Date: March 11, 2025.**

Limited Submissions

Only one application per institution is allowed for the following FOAs and prior approval from the OVPR is required to be the sole applicant. If interested in applying, please provide the OVPRED with notification 60 days prior to the deadline to ovpr.limitedsubmission@research.buffalo.edu before proceeding with the application.

Visit the Limited Competition [website](#) for the latest open competitions including the **Highmark Blue Fund**.

[Limited Submission Funding Opportunities](#)

Prior Research Opportunities can be found on the SPHHP RAS website and by clicking the link below:

[Research Opportunities from Past Newsletters](#)

Words to Live By

“Ability is what you're capable of doing. Motivation determines what you do. Attitude determines how well you do it.”

- Raymond Chandler

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras